Johnson & Johnson (JNJ) said Wednesday that results from a phase 3 trial showed that Rybrevant as a conjugate therapy "significantly extended" overall survival in certain cancer patients.
The drug was studied in combination Lazcluze as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer, NSCLC, compared with osimertinib and Lazcluze as a monotherapy, according to the statement.
Patients treated with the chemotherapy-free regimen of the Rybrevant-Lazcluze combination had a significantly longer overall survival compared with those treated with osimertinib at the study's median follow-up of 37.8 months. Median overall survival has not yet been reached, indicating that the combination therapy's survival benefits extend beyond the measured follow-up period.
The company expects median overall survival from the Rybrevant and Lazcluze to surpass the three-year median observed with osimertinib by a year.
Johnson & Johnson said the phase 3 study achieved its primary endpoint in October 2023 and that it plans to share the study's overall survival results with health authorities globally.
Rybrevant plus Lazcluze is approved in the US, Europe, and other markets for patients with EGFR-mutated NSCLC, according to the statement.
Price: 161.71, Change: +0.69, Percent Change: +0.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.